Janina Baranowska-Kortylewicz, PhD

janina-baranowska-kortylewicz.jpg

Research Professor

Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986025 Nebraska Medical Center
Omaha, NE 68198-6025
402-559-8906(Office)
Email

Teaching Activities:
Dr. Baranowska-Kortylewicz lectured in radiation chemistry and biology (MITS 438/638N and RSTE 438N) from 1993 until 2019.

Research Activities/Interests:
Research activities of Dr. Baranowska-Kortylewicz’s laboratory are focused on the development of theranostics for individualized treatment of cancer with a special emphasis on the design and development of radiopharmaceuticals safe for the use in pediatric patients. Our ongoing projects also include the identification of novel tumor-associated biomarkers and development of theranostics that can target these markers.

Recent Publications:

  1. Baranowska-Kortylewicz J, Kortylewicz ZP, McIntyre EM, Sharp JG, Coulter DW. Multifarious Functions of Butyrylcholinesterase in Neuroblastoma: Impact of BCHE deletion on the neuroblastoma growth in vitro and in vivo. J Pediatr Hematol Oncol. 2021 Sep 6. Online ahead of print. PMID: 34486544.
  2. Kortylewicz ZP, Coulter DW, Han G, Baranowska-Kortylewicz J. Radiolabeled (R)-(-)-5-iodo-3'-O-[2-(ε-guanidinohexanoyl)-2-phenylacetyl]-2'-deoxyuridine: A new theranostic for neuroblastoma. J Labelled Comp Radiopharm. 2020; 63:312-324. PMID: 32150284.
  3. Baranowska-Kortylewicz J, Sharp JG, McGuire TR, Joshi S, Coulter DW. Alpha-Particle therapy for multifocal osteosarcoma: A hypothesis. Cancer Biother Radiopharm. 2020; 35:418-424. PMID: 32073902.
  4. Kortylewicz ZP, Coulter DW, Han G, Baranowska-Kortylewicz J. Norepinephrine-transporter-targeted and DNA-co-targeted theranostic guanidines. J Med Chem. 2020; 63:2051-2073. PMID: 31268317. This article is included in the Women in Medicinal Chemistry Special Issue.
  5. Kortylewicz ZP, Coulter DW, Baranowska-Kortylewicz J. In vitro and in vivo evaluation of radiolabeled methyl N-[5-(3'-halobenzoyl)-1H-benzimidazol-2-yl]carbamate for cancer radiotherapy. Drug Dev Res. 2020; 81:62-69. PMID: 31593323.
  6. Kortylewicz ZP, Coulter DW, Baranowska-Kortylewicz J. Biological evaluation of a potential anticancer agent methyl N-[5-(3'-iodobenzoyl)-1H-benzimidazol-2-yl]carbamate. Cancer Biother Radiopharm. 2020; 35:16-25. PMID: 31687840.
  7. Kortylewicz ZP, Baranowska‐Kortylewicz J. Radiosynthesis of microtubule‐targeted theranostic methyl N‐[5‐(3’‐radiohalobenzoyl)‐1H‐benzimidazol‐2‐yl] carbamates. J Label Compd Radiopharm. 2018; 61:749–756.
  8. Dalrymple GV, Kortylewicz ZP, Baranowska-Kortylewicz J. DNA-targeted molecular radiotherapy for ovarian cancer. New Horiz Transl Med. 2017; 4:52-53. https://doi.org/10.1016/j.nhtm. 2017. 11.001
  9. Coulter DW, Boettner AD, Kortylewicz ZP, Enke SP, Luther JA, Verma V, Baranowska-Kortylewicz J. Butyrylcholinesterase as a blood biomarker in neuroblastoma. J Pediatric Hematol Oncol. 2017; 39:272-281. PMID: 28375942.
  10. Kortylewicz ZP, Mack E, Enke CA, Estes KA, Mosley RL, Baranowska-Kortylewicz J. Preclinical evaluation of investigational radiopharmaceutical RISAD-P intended for use as a diagnostic and molecular radiotherapy agent for prostate cancer Prostate. 2015; 75:8-22. PMID: 25283970.